Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 10/20 | 0.64 |
| ▸ | F13A1 | P00488 | 7/20 | 0.64 |
| ▸ | TGM1 | P22735 | 4/20 | 0.59 |
| ▸ | PKM | P14618 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1684972 | 0.95 | TGM2 (0.69) | TGM2F13A1TGM1PKMPOLB | |
| SCHEMBL1955697 | 0.89 | ALDH1A1 (0.62) | TGM2F13A1TGM1PKMPOLB | |
| SCHEMBL12550181 | 0.88 | LMNA (0.60) | TGM2F13A1TGM1POLB | |
| SCHEMBL14490210 | 0.88 | TGM2 (0.59) | TGM2F13A1TGM1PKM | |
| SCHEMBL1955143 | 0.87 | TGM2 (0.58) | TGM2F13A1TGM1PKMMEN1 | |
| SCHEMBL24693750 | 0.85 | TGM2 (0.56) | TGM2F13A1TGM1PKMPOLB | |
| SCHEMBL6977995 | 0.85 | TGM2 (0.58) | TGM2F13A1TGM1POLB | |
| SCHEMBL27200534 | 0.85 | TGM2 (0.64) | TGM2F13A1TGM1PKMPOLB | |
| SCHEMBL18410584 | 0.83 | TGM2 (0.65) | TGM2F13A1TGM1PKMPOLB | |
| SCHEMBL23788561 | 0.82 | ALDH1A1 (0.62) | TGM2F13A1TGM1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420630-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | disclosed |
| EP-2332924-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-2090571-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-08-19 | — | — | EP | disclosed |
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (UK) | 2008-09-25 | — | — | US | disclosed |
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (UK) | 2008-09-25 | — | — | US | disclosed |
| EP-1438053-B1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-7173028-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-06 | — | — | US | disclosed |
| US-20060100211-A1 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | disclosed |
| EP-1438053-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-21 | — | — | EP | disclosed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | disclosed |
| WO-2003032997-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100211-A1 | Pyrimidine derivatives | TYMP, TYMS, DPYD | TGM2 3077/4885F13A1 4649/4885TGM1 2949/4885 |
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | HIF1AN, HIF1A, CDK2 | TGM2 3590/4885F13A1 3909/4885TGM1 2417/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | TGM2 2997/4885F13A1 3297/4885TGM1 2346/4885 |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | TGM2 3077/4885F13A1 4649/4885TGM1 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.